The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats

Synapse

Volumn 63, Issue 7, 2009, Pages 610-620

  Eskow, Karen L ^a   Dupre, Kristin B ^a   Barnum, Christopher J ^a   Dickinson, Sando O ^a   Park, John Y ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

DA; Dyskinesia; L dopa; Parkinson's disease; Raphe nuclei; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BENSERAZIDE; DESIPRAMINE; DOPAMINE; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1 AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN STEM; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED DYSKINESIA; DRUG INDUCED HEMIPARKINSONISM; MALE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; ROSTRAL RAPHE NUCLEUS; STRIATONIGRAL DEGENERATION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DOPAMINE; DYSKINESIA, DRUG-INDUCED; HYDROXYINDOLEACETIC ACID; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; NEURONS; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN AGENTS;

EID: 67449107965     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20630     Document Type: Article

References (50)

1. Arai R, Karasawa N, Nagatsu I. 1996. Dopamine produced from L-dopa is degraded by endogenous monoamine oxidase in neurons of the dorsal raphe nucleus of the rat: An immunonistochemical study. Brain Res 722:181-184. (Pubitemid 26199366)
2. Arai R, Horiike K, Hasegawa Y. 1998. Dopamine-degrading activity of monoamine oxidase in locus coeruleus and dorsal raphe nucleus neurons. A histochemical study in the rat. Neurosci Lett 250:41-44.
3. Azmitia EC, Segal M. 1978. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 179:641-668. (Pubitemid 8372646)
4. Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN. 2005. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 20:932-936. (Pubitemid 41419506)
5. Bert B, Fink H, Hörtnagl H, Veh RW, Davies B, Theuring F, Kusserow H. 2006. Mice over-expressing the 5-HT(1A) receptor in cortex and dentate gyrus display exaggerated locomotor and hypothermic response to 8-OH-DPAT. Behav Brain Res 167:328-341.
6. Bibbiani F, Oh JD, Chase TN. 2001. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829-1834. (Pubitemid 33096691)
7. Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD. 2006. MDMA and fenfluramine reduce L-dopa-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 23:2669-2676. (Pubitemid 43801458)
8. Blanchard RJ, Shepherd JK, Armstrong J, Tsuda SF, Blanchard DC. 1993. An ethopharmacological analysis of the behavioral effects of 8-OH-DPAT. Psychopharmacology (Berl) 112:55-63. (Pubitemid 23261856)
9. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. 1994. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17:73-82.
10. Carey R, Depalma G, Damianopoulos E, Muller C, Huston J. 2004. The 5-HT1A receptor and behavioral stimulation in the rat: Effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology (Berl) 177:46-54. (Pubitemid 40109913)
11. Carlsson T, Carta M, Winkler C, Björklund A, Kirik D. 2007. Serotonin neuron transplants exacerbate L-dopa-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 27:8011-8022. (Pubitemid 47173327)
12. Carta M, Carlsson T, Kirik D, Björklund A. 2007. Dopamine released from 5-HT terminals is the cause of L-dopa-induced dyskinesia in parkinsonian rats. Brain 130:1819-1833. (Pubitemid 47343795)
13. Cenci M, Lundblad M. 2006. Post- versus presynaptic plasticity in L-dopa-induced dyskinesia. J Neurochem 99:381-392. (Pubitemid 44477196)
14. Chang JW, Wachtel SR, Young D, Kang UJ. 1999. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617-628. (Pubitemid 28480020)
15. Cosi C, Koek W. 2000. The putative "silent" 5-HT1A receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT1A receptors. Eur J Pharmacol 401:9-15. (Pubitemid 30479806)
16. Dupre KB, Eskow KL, Negron G, Bishop C. 2007. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158:135-143. (Pubitemid 47068412)
17. Eskow KL, Gupta V, Alam S, Park JY, Bishop C. 2007. The partial 5-HT(1A) agonist buspirone reduces the expression and development of L-dopa-induced dyskinesia in rats and improves L-dopa efficacy. Pharmacol Biochem Behav 87:306-314.
18. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A. 1995. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281: 81-88.
19. Fox SH, Lang AE, Brotchie JM. 2007. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to Phase IIa clinical studies: Keys to success and roads to failure. Mov Disord 21:1578-1594. (Pubitemid 44742184)
20. Gershanik O, Heikkila R, Duvoisin R. 1979. The role of serotonin neurons in the action of L-dopa in an animal model of parkinsonism. Neurology 29:553. (Pubitemid 9145810)
21. Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. 2007. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. Mov Disord 22:179-186. (Pubitemid 46374758)
22. Goodwin GM, De Souza RJ, Green AR, Heal DJ. 1987. The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Psychopharmacology (Berl) 91:506-511. (Pubitemid 17038217)
23. Guerra MJ, Liste I, Labandeira-Garcia JL. 1997. Effects of lesions of the nigrostriatal pathway and of nigral grafts on striatal serotonergic innervation in adult rats. Neuroreport 8:3485-3488. (Pubitemid 27497469)
24. Hornung JP. 2003. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 26:331-343. (Pubitemid 38077156)
25. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. 2006. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. Pharmacol Exp Ther 319:1225-1234.
26. Jankovic J. 2005. Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations. Mov Disord 20:S11-S16. (Pubitemid 40846906)
27. Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M. 2001. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-dopa in the striatum with nigrostriatal denervation. J Neurochem 76:1346-1353. (Pubitemid 32198239)
28. Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M. 2002. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-dopa-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54:133-137.
29. Kannari K, Shen H, Arai A, Tomiyama M, Baba M. 2006. Reuptake of L-dopa-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett 402:62-65. (Pubitemid 43766440)
30. Kilpatrick IC, Jones MW, Phillipson OT. 1986. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: An isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 46:1865-1876. (Pubitemid 16095494)
31. Kreiss DS, Lucki L. 1994. Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei. J Pharm Exp Ther 269:1268-1279. (Pubitemid 24204214)
32. Lanfurney L, Hamon M. 2000. Central 5-HT(1A) receptors: Regional distribution and functional characteristics. Nucl Med Biol 27:429-435. (Pubitemid 30658142)
33. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. 2002. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132. (Pubitemid 35478015)
34. Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M, Suda T. 2003. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 343:17-20. (Pubitemid 36577202)
35. Maeda T, Nagata K, Yoshida Y, Kannari K. 2005. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-dopa. Brain Res 1046:230-233. (Pubitemid 40775894)
36. Mamounas LA, Mullen CA, O'Hearn E, Molliver ME. 1991. Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 314:558-586.
37. Matsubara K, Shimizu K, Suno M, Ogawa K, Awaya T, Yamada T, Noda T, Satomi M, Ohtaki K, Chiba K, Tasaki Y, Shiono H. 2006. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 1112:126-133. (Pubitemid 44344618)
38. McQuade R, Sharp T. 1997. Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J Neurochem 69:791-796. (Pubitemid 27327983)
39. Ng K, Chase T, Colburn R, Kopin I. 1971. Dopamine stimulation-induced release from central neurons. Science 172:487-489.
40. Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H. 2004. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27:58-62.
41. Olsson M, Nikkhah G, Bentlage C, Björklund A. 1995. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863-3875.
42. Paxinos G, Watson W. 1998. The rat brain in stereotaxic coordinates, 4th ed. San Diego: Academic Press.
43. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X, el Mestikawy S, Hamon M, Descarries L. 2000. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 417:181-194.
44. Sato S, Koitabashi T, Koshiro A. 1994. Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. II. Effect of L-dopa on dopamine and dopamine metabolite concentration in rat striatum. Biol Pharm Bull 17:1622-1629.
45. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. 1999. Role of serotonergic neurons in L-dopa-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10:631-634. (Pubitemid 29333295)
46. Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M. 2005. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci Res 52:185-194. (Pubitemid 40704601)
47. Yamato H, Kannari K, Shen H, Suda T, Matsunaga M. 2001. Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport 12:1123-1126. (Pubitemid 32374729)
48. Yu H, Lewander T. 1997. Pharmacokinetic and pharmacodynamic studies of (R)-8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur Neuropsychopharmacol 7:165-172. (Pubitemid 27278484)
49. Zhang X, Andren P, Greengard P, Svenningsson P. 2008. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-dopa treatment of an animal model of Parkinsonism. Proc Natl Acad Sci USA 105:2163-2168.
50. Zhou FC, Bledsoe S, Murphy J. 1991. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556:108-116.